Press Releases - Supernus Pharmaceuticals

News Category

Year

Date	Title
September 2, 2026	Supernus Pharmaceuticals to Participate in September Investor Conferences	PDF Version
August 31, 2026	Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD	PDF Version
August 3, 2026	Supernus Announces Second Quarter 2026 Financial Results	PDF Version
August 3, 2026	Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale	PDF Version
July 22, 2026	Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026	PDF Version
July 14, 2026	Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD	PDF Version
May 27, 2026	Supernus Pharmaceuticals to Participate in June Investor Conferences	PDF Version
May 6, 2026	Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference	PDF Version
May 5, 2026	Supernus Announces First Quarter 2026 Financial Results	PDF Version
April 22, 2026	Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026	PDF Version